- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05020964
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
The hypothesis of this study is to discover the efficacy and safety of trastuzumab combined with pyrotinib in treating advanced breast cancer with HER2 positive, which is detected by digital PCR. It is a single-arm, multicenter phase II clinical study.
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yuan Peng
- Phone Number: 01087787245
- Email: yuanpeng01@hotmail.com
Study Contact Backup
- Name: Yi-Kun Kang
- Phone Number: 18911611553
- Email: 345890335@qqq.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with recurrent or distant metastatic breast cancer whose primary tissue was negative for HER2 amplification, and newly diagnosed patients with stage IV breast cancer who were negative for HER2 amplification; All enrolled patients had previously received ≥ second-line therapy; Note: ① negative expression of HER2 refers to the primary tissue tested by IHC/FISH (clinical report), and the cell immunohistochemical staining intensity is 0,1 + or 2+, but negative by fluorescence in situ hybridization (FISH).
- Age range 18-75, female;
- Good physical strength: ECOG score 0-1;
- Expected survival of more than 3 months;
- The patient had no major organ dysfunction;Include: Routine blood The ANC acuity 1.5 x 109 / L;PLT acuity 90 x 109 / L;Hb 90 g/L or higher; Blood biochemical 1.5 x ULN TBIL or less;ALT and AST 2 x ULN or less;ALT and AST≤5×ULN in patients with liver metastases;BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); Heart colour to exceed LVEF 50% or higher;Fridericia adjusted QT interval (QTcF) for 12-lead electrocardiogram in men < 450 ms and in women < 470 ms.
- Evaluable tumor lesions according to RECIST 1.1 criteria;
- Voluntarily join the group, agree and sign the written informed consent.
Exclusion Criteria:
- Patients who have previously received anti-HER2 therapy, or who have received a study drug or preparation/treatment (i.e., participating in another trial) within 4 weeks prior to enrollment;
- Patients who are allergic to study drugs or unable to take them orally;Patients who refuse the medication regimen;
- Serious dysfunction of vital organs (heart, liver, kidney);Clinically significant heart disease, i.e., New York Heart Association (NYHA) grade ⅲ - ⅳ heart failure or more severe congestive heart failure or severe arrhythmias requiring pharmacological intervention;Uncontrollable angina pectoris, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction within 6 months as confirmed by electrocardiogram (ECG);Previous history of organ transplantation, splenectomy;
- Patients with other malignancies, except for cured non-melanoma skin cancers, cervical carcinoma in situ and other tumors that have been cured for at least 5 years;
- Pregnant and lactating women (women of childbearing age are subject to pregnancy tests), fertile women with positive baseline pregnancy tests, or women of childbearing age who are unwilling to use effective contraception throughout the study period.;
- In the active period of other acute infectious diseases or chronic infectious diseases;
- A history of uncontrolled epilepsy, central nervous system disease or mental disorder;
- Persons with disabilities of consciousness and other legal capacity or legal capacity limited;
- A known history of human immunodeficiency virus;
- Other conditions that the investigator considers inappropriate for the patient to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental Arm
Trastuzumab and Pyrotinib
|
Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle. Use until intolerable toxicity or disease progression occurs. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate(ORR)
Time Frame: up to 1 year after the last patient enrolled
|
The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)
|
up to 1 year after the last patient enrolled
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival(PFS)
Time Frame: up to 1 year after the last patient enrolled
|
PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause
|
up to 1 year after the last patient enrolled
|
Incidence and Severity of adverse events
Time Frame: approximately 1.5 years
|
hematologic, hepatotoxicity, Incidence of hypertension, Incidence of proteinuria
|
approximately 1.5 years
|
Collaborators and Investigators
Investigators
- Study Chair: Yuan Peng, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC1888
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
-
SanofiCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast CancerUnited States
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerJapan
Clinical Trials on Trastuzumab and Pyrotinib
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaboratorsUnknownColorectal CancerChina
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
Fudan UniversityRecruitingEffect of Drug | Gastrointestinal TumorChina
-
xuexin heNot yet recruitingHER2-positive Breast Cancer
-
Huihua XiongNot yet recruiting
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Fudan UniversityCompleted
-
Zhejiang Cancer HospitalRecruiting
-
Cancer Institute and Hospital, Chinese Academy...RecruitingCarcinoma, Transitional Cell | HER-2 Gene AmplificationChina
-
Shengjing HospitalNot yet recruiting